BACKGROUND: An association has been demonstrated between herpes simplex type 2 (HSV-2) and HIV infection among men, but prospective studies in women have yielded mixed results. OBJECTIVE: To estimate the effects of prevalent and incident HSV-2 infection on subsequent HIV acquisition among women in two African countries. DESIGN: Prospective cohort study. METHODS: HSV-2 and HIV serostatus were evaluated at enrollment and quarterly for 15-24 months among 4531 sexually active, HIV-uninfected women aged 18-35 years from Uganda and Zimbabwe. The association between prior HSV-2 infection and HIV acquisition was estimated using a marginal structural discrete survival model, adjusted for covariates. RESULTS: HSV-2 seroprevalence at enrollment was 52% in Uganda and 53% in Zimbabwe; seroincidence during follow-up was 9.6 and 8.8/100 person-years in Uganda and Zimbabwe, respectively. In Uganda, the hazard ratio (HR) for HIV was 2.8 [95% confidence interval (CI), 1.5-5.3] among women with seroprevalent HSV-2 and 4.6 (95% CI, 1.6-13.1) among women with seroincident HSV-2, adjusted for confounding. In Zimbabwe, the HR for HIV was 4.4 (95% CI, 2.7-7.2) among women with seroprevalent HSV-2, and 8.6 (95% CI, 4.3-17.1) among women with seroincident HSV-2, adjusted for confounding. The population attributable risk percent for HIV due to prevalent and incident HSV-2 infection was 42% in Uganda and 65% in Zimbabwe. CONCLUSIONS: HSV-2 plays an important role in the acquisition of HIV among women. Efforts to implement known HSV-2 control measures, as well as identify additional measures to control HSV-2, are urgently needed to curb the spread of HIV.
BACKGROUND: An association has been demonstrated between herpes simplex type 2 (HSV-2) and HIV infection among men, but prospective studies in women have yielded mixed results. OBJECTIVE: To estimate the effects of prevalent and incident HSV-2 infection on subsequent HIV acquisition among women in two African countries. DESIGN: Prospective cohort study. METHODS:HSV-2 and HIV serostatus were evaluated at enrollment and quarterly for 15-24 months among 4531 sexually active, HIV-uninfectedwomen aged 18-35 years from Uganda and Zimbabwe. The association between prior HSV-2 infection and HIV acquisition was estimated using a marginal structural discrete survival model, adjusted for covariates. RESULTS:HSV-2 seroprevalence at enrollment was 52% in Uganda and 53% in Zimbabwe; seroincidence during follow-up was 9.6 and 8.8/100 person-years in Uganda and Zimbabwe, respectively. In Uganda, the hazard ratio (HR) for HIV was 2.8 [95% confidence interval (CI), 1.5-5.3] among women with seroprevalent HSV-2 and 4.6 (95% CI, 1.6-13.1) among women with seroincident HSV-2, adjusted for confounding. In Zimbabwe, the HR for HIV was 4.4 (95% CI, 2.7-7.2) among women with seroprevalent HSV-2, and 8.6 (95% CI, 4.3-17.1) among women with seroincident HSV-2, adjusted for confounding. The population attributable risk percent for HIV due to prevalent and incident HSV-2 infection was 42% in Uganda and 65% in Zimbabwe. CONCLUSIONS:HSV-2 plays an important role in the acquisition of HIV among women. Efforts to implement known HSV-2 control measures, as well as identify additional measures to control HSV-2, are urgently needed to curb the spread of HIV.
Authors: M Eugenia Socías; Putu Duff; Jean Shoveller; Julio S G Montaner; Paul Nguyen; Gina Ogilvie; Kate Shannon Journal: Sex Transm Infect Date: 2016-11-07 Impact factor: 3.519
Authors: Alexis M Roth; Barbara Van Der Pol; J Dennis Fortenberry; Brian Dodge; Michael Reece; David Certo; Gregory D Zimet Journal: J Health Commun Date: 2014-12-12
Authors: Yo Hoshino; Lesley Pesnicak; Kennichi C Dowdell; Juan Lacayo; Timothy Dudek; David M Knipe; Stephen E Straus; Jeffrey I Cohen Journal: Vaccine Date: 2008-06-02 Impact factor: 3.641
Authors: David Tyssen; Scott A Henderson; Adam Johnson; Jasminka Sterjovski; Katie Moore; Jennifer La; Mark Zanin; Secondo Sonza; Peter Karellas; Michael P Giannis; Guy Krippner; Steve Wesselingh; Tom McCarthy; Paul R Gorry; Paul A Ramsland; Richard Cone; Jeremy R A Paull; Gareth R Lewis; Gilda Tachedjian Journal: PLoS One Date: 2010-08-23 Impact factor: 3.240
Authors: Marshall W Munjoma; Edith N Kurewa; Munyaradzi P Mapingure; Grace V Mashavave; Mike Z Chirenje; Simbarashe Rusakaniko; Akhtar Hussain; Babill Stray-Pedersen Journal: BMC Womens Health Date: 2010-01-12 Impact factor: 2.809